Related Experiment Videos

Fibrogenesis imperfecta ossium: ineffectiveness of melphalan

M Lafage-Proust1, T Schaeverbeke, J Dehais

  • 1Laboratoire de Biologie du Tissu Osseux, Faculté de Médecine, 15 rue A. Paré, 42023 Saint-Etienne, Cedex 2, France.

Insights

Fibrogenesis imperfecta ossium (FIO), a rare bone disorder, may be linked to monoclonal gammopathy (MCG). This association suggests plasma cells could impair bone collagen formation, leading to fractures.

Area of Science:

  • Bone biology
  • Metabolic bone diseases
  • Connective tissue disorders

Background:

  • Fibrogenesis imperfecta ossium (FIO) is an extremely rare metabolic bone disease characterized by collagen defects and spontaneous fractures.
  • Monoclonal gammopathy (MCG) has been observed in a subset of FIO patients, suggesting a potential link.

Observation:

  • A 56-year-old woman presented with spontaneous fractures, abnormal bone histology consistent with FIO, and monoclonal IgG kappa light chain.
  • Skeletal X-rays revealed coarse, ill-defined trabeculae, and bone biopsy showed osteomalacia and increased eroded surfaces.

Findings:

  • Despite treatment with melphalan, the patient's condition worsened, with persistent FIO features and new fractures.
  • The co-occurrence of FIO and MCG in this case, and previously reported cases, suggests their association is unlikely coincidental.

Implications:

  • The findings suggest a potential role for plasma cell dyscrasia in FIO pathogenesis.
  • This association may indicate that plasma cell-derived factors could impair osteoblast function and bone matrix collagen synthesis.

Related Concept Videos